30.90
-1.8(-5.50%)
Currency In USD
| Previous Close | 32.7 |
| Open | 33.28 |
| Day High | 34.24 |
| Day Low | 30.81 |
| 52-Week High | 62.53 |
| 52-Week Low | 24.1 |
| Volume | 852,032 |
| Average Volume | 1.01M |
| Market Cap | 2.89B |
| PE | -8.37 |
| EPS | -3.69 |
| Moving Average 50 Days | 32.41 |
| Moving Average 200 Days | 46.09 |
| Change | -1.8 |
If you invested $1000 in Crinetics Pharmaceuticals, Inc. (CRNX) since IPO date, it would be worth $1,260.71 as of May 09, 2025 at a share price of $30.9. Whereas If you bought $1000 worth of Crinetics Pharmaceuticals, Inc. (CRNX) shares 5 years ago, it would be worth $1,592.78 as of May 09, 2025 at a share price of $30.9.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Crinetics Pharmaceuticals to Report First Quarter 2025 Financial Results on May 8, 2025
GlobeNewswire Inc.
Apr 11, 2025 12:00 PM GMT
SAN DIEGO, April 11, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report first quarter 2025 financial results on Thursday, May 8, 2025 after the market closes. Company management will host a c
Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire Inc.
Apr 10, 2025 9:04 PM GMT
SAN DIEGO, April 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on April 10, 2025, the Compensation Committee of the Board of Directors granted non-qualified stock option awards to purchase an aggre
Crinetics Pharmaceuticals Announces European Medicines Agency (EMA) Validation of Marketing Authorization Application (MAA) and Orphan Drug Designation (ODD) for Paltusotine in Acromegaly
GlobeNewswire Inc.
Mar 27, 2025 8:05 PM GMT
SAN DIEGO, March 27, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for paltusotine, the first once-daily,